# US 2024/0197860 A1 · Self-replicating rna and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197860 A1
- Document ID: US20240197860A1
- Status: Published application
- Kind: A1
- Application number: 18/512,730
- Filed: 2023-11-17
- Published: 2024-06-20
- Earliest claimed: 2022-11-18
- Assignees: Trustees of Boston University
- Applicants: Trustees of Boston University
- Inventors: Joshua Edward MCGEE; Jack Rainier KIRSCH; Eric BRESSLER; Mark W. GRINSTAFF; Wilson WONG; Lidya Yidnekachew Sertse; Kexin Li
- Web page: https://patentgrep.com/patent/US20240197860A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- C12N 15/67: General methods for enhancing the expression
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/32: against translation products of oncogenes
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/86: Viral vectors
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2239/10: characterized by the structure of the chimeric antigen receptor [CAR]
- A61K 2239/22: Intracellular domain
- A61K 2239/23: On/off switch
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/49: Breast
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/203: having an IRES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The technology described herein is directed to compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA (saRNA). Also described herein are compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA that is substituted with chemically modified nucleotides.

## Claims

### Claim 1

A self-amplifying RNA (saRNA) comprising at least 25% modified nucleotides, wherein the modified nucleotides comprise a pyrimidine nucleoside phosphate with a moiety on carbon 5 of the pyrimidine, wherein the moiety is selected from the group consisting of methyl, ethyl, propyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, and hydroxypropyl functional groups, and at least one cargo of interest.

### Claim 2 (depends on 1)

The saRNA of claim 1, wherein the modified nucleotides comprise 5-methylcytidine, 5-methyluridine, 5-hydroxymethyluridine, 5-hydroxymethylcytidine or a combination thereof.

### Claim 3 (depends on 1)

The saRNA of claim 1, wherein the saRNA expresses the cargo at a level greater than or equal to that of a corresponding saRNA with less than 25% modified nucleotides.

### Claim 4 (depends on 1)

The saRNA of claim 1, wherein the level of substitution of the modified nucleotides is: 25%-50%; 51%-75%; 75%-99%; 99.1%-99.9%; or 100%.

### Claim 5 (depends on 1)

The saRNA of claim 1, wherein the initiating nucleotide comprises:
(a) an adenosine or adenosine analog, and wherein the initiating nucleotide of the saRNA is methylated at the 2′O position of the ribose (Cap1):
(b) an adenosine or adenosine analog, and wherein the initiating nucleotide and the subsequent nucleotide of the saRNA are both methylated at the 2′O position of the ribose (Cap2);
(c) a guanosine or guanosine analog, and wherein the initiating nucleotide of the saRNA is methylated at the 2′O position of the ribose (Cap1): or
(d) a guanosine or guanosine analog, and wherein the initiating nucleotide and the subsequent nucleotide of the saRNA are both methylated at the 2′O position of the ribose (Cap2).

### Claim 6 (depends on 1)

The saRNA of claim 1 comprising from 5′ to 3″:
(a) a 5′ cap:
(b) non-structural protein 1 (nsp1), non-structural protein 2 (nsp2), non-structural protein 3 (nsp3), and/or non-structural protein 4 (nsp4), each derived from at least one virus;
(c) a subgenomic promoter (SGP) derived from at least one virus;
(d) 5′ untranslated region (UTR) derived from at least one virus;
(e) the at least one cargo of interest;
(f) a 3′ untranslated region (UTR) derived from at least one virus; and
(g) a poly-A tail.

### Claim 7 (depends on 1)

The saRNA of claim 1, further comprising at least one 5′ conserved sequence element (CSE) and/or 3′ at least one conserved sequence element (CSE) derived from at least one virus.

### Claim 8 (depends on 6)

The saRNA of claim 6, wherein the at least one virus is an alphavirus.

### Claim 9 (depends on 6)

The saRNA of claim 6, wherein the at least one virus is selected from the group consisting of: Venezuela Equine Encephalitis Virus (VEEV), Semliki Forest Virus (SFV), Sindbis Virus (SIN), Chikungunya Virus (CHIKV), Eastern Equine Encephalitis Virus (EEEV), Mayaro Virus (MAYV), Getah Virus (GETV), Ross River Virus (RRV), Una Virus (UNAV), Middleburg Virus (MIDV), O'nyong nyong virus (ONNV), Barmah Forest Virus (BFV), Mucambo Virus (MUCV), Tonate Virus (TONV), Everglades Virus (EVEV), Rio Negro Virus (RNV), Turnip Rosette Virus (TROV), Highlands J Virus (HJV), Western Equine Encephalitis Virus (WEEV), Fig Mosaic Emaravirus (FMV), Aura Virus (AURAV), Kunjin Virus (KUN), Measles virus (MV), Coronavirus (CoV), Rabies virus (RABV), and Vesicular Stomatitis virus (VSV).

### Claim 10 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises a chimeric antigen receptor (CAR) comprising an extracellular domain that specifically binds to an antigen of interest.

### Claim 11 (depends on 10)

The saRNA of claim 10, wherein the antigen of interest for the CAR is selected from the group consisting of: CD19, CD22, CD30, b-cell maturation antigen (BCMA), disialoganglioside GD2, human estrogen receptor 2 (HER2), G protein-coupled receptor 87 (GPR87), Fibroblast Activator Protein (FAP), CD20, receptor tyrosine kinase-like orphan receptor 1 (ROR1), carcinoembryonic antigen (CEA), mesothelin (MSLN), prostate-specific membrane antigen (PSMA), epidermal growth factor receptor variant III (EGFRvIII), Interleukin 13 receptor alpha 2 (IL13Rα2), and natural killer group 2 member D (NKG2D).

### Claim 12 (depends on 10)

The saRNA of claim 10, wherein the CAR is selected from the group consisting of:
(a) a conventional CAR;
(b) an ON-CAR;
(c) an OFF-CAR system;
(d) an ON/OFF-CAR;
(e) an inhibitory CAR; or
(f) a split, universal, programmable and reconfigurable (SUPRA) CAR system.

### Claim 13 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises a ligand, a cell surface receptor, a transcription factor, a cytokine, a chemokine, an enzyme, and/or an antibody or fragment thereof.

### Claim 14 (depends on 13)

The saRNA of claim 13, wherein the antibody is a bispecific antibody.

### Claim 15 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises a bispecific T cell engager (BiTE).

### Claim 16 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one non-coding RNA selected from the group consisting of siRNA, shRNA, and microRNA.

### Claim 17 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one vaccine-associated antigen comprising at least one protein encoded by a genome of a virus.

### Claim 18 (depends on 17)

The saRNA of claim 17, wherein the virus is selected from the group consisting of: Rift valley fever, Crimean-Congo haemorrhagic fever, Lassa fever, Chikungunya Virus (CHIKV), Nipah Virus (NiV), respiratory syncytial virus (RSV), Ebola virus, Marburg virus, West Nile virus, Venezuela equine encephalitis, yellow fever virus, Japanese encephalitis virus, western equine encephalitis virus, eastern equine encephalitis, cytomegalovirus (CMV), human immunodeficiency virus (HIV), influenza virus, Zika virus, middle eastern respiratory syndrome coronavirus (MERS-COV), severe acute respiratory syndrome coronavirus (SARS-COV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), human papillomavirus (HPV), herpes virus, rotavirus, varicella-zoster virus (VZV), dengue virus, hepatitis A virus, hepatitis B virus, rubella virus, poliovirus, and rabies virus.

### Claim 19 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one transcription factor selected from the group consisting of Octamer-Binding Transcription Factor 3 (Oct3, Oct4), Sex-Determining Region Y (SRY)-Box Transcription Factor 2 (Sox2), Kruppel-Like Factor 4 (Klf4), and cellular myelocytomatosis oncogene (c-Myc).

### Claim 20 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one growth factor and/or cytokine selected from the group consisting of platelet-derived growth factor (PDGF), erythropoietin (EPO), vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), fibroblast growth factor (FGF), human relaxin-2 (RLX2), alpha-melanocyte-stimulating hormone (alpha-MSH), insulin-like growth factor-I (IGF-I), epidermal growth factor (EGF), nerve growth factor (NGF), granulocyte-monocyte colony-stimulating factor (GMCSF), Thrombopoietin (TPO), Bone morphogenic protein (BMP), hepatocyte growth factor (HGF), growth/differentiation factor (GDF), a Neurotrophin, migration stimulating factor (MSF), and sarcoma growth factor (SGF); or wherein the cargo comprises one or both of Pappalysin-A1 (PAPPA1) and Pappalysin-A2 (PAPPA2).

### Claim 21 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one interleukin and/or a cognate receptor(s) of the interleukin and/or receptor sub-units for the interleukin, wherein the interleukin is selected from the group consisting of IL-2, IL-4, IL-7, IL-10, IL-12, IL-13, and IL-15.

### Claim 22 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises at least one enzyme with antioxidant activity, wherein the enzyme is selected from the group consisting of phospholipid hydroperoxide glutathione peroxidase, superoxide dismutase-1, superoxide dismutase-2, Bruton's tyrosine kinase, adenosine deaminase, and ecto-nucleoside triphosphate diphosphydrolase.

### Claim 23 (depends on 1)

The saRNA of claim 1, wherein the cargo comprises glucagon-like peptide-1 (GLP-1) or a fragment thereof.

### Claim 24

A self-amplifying RNA (saRNA) comprising from 5′ to 3″:
(a) a 5′ cap;
(b) non-structural protein 1 (nsp1), non-structural protein 2 (nsp2), non-structural protein 3 (nsp3), and/or non-structural protein 4 (nsp4), each derived from at least one virus;
(c) a subgenomic promoter (SGP) derived from at least one virus;
(d) a 5′ untranslated region (UTR) derived from at least one virus;
(e) at least one cargo of interest;
(f) a 3′ untranslated region (UTR) derived from at least one virus; and
(g) a poly-A tail.

### Claim 25 (depends on 1)

A nucleic acid, vector, or cell encoding or comprising the saRNA of claim 1.

### Claim 26 (depends on 1)

A pharmaceutical composition comprising the saRNA of claim 1 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 1)

A method of expressing at least one cargo of interest in a cell, the method comprising contacting the cell with the saRNA of claim 1.

### Claim 28 (depends on 27)

The method of claim 27, the method further comprising contacting the cell with at least one input to control the fate or function of the cell.

### Claim 29 (depends on 26)

A method of expressing at least one cargo in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 26.

### Claim 30 (depends on 29)

The method of claim 29, the method further comprising administering to the subject at least one input to control the fate or function of at least one cell in the subject.
